Cue Biopharma Inc(CUE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -27 | Insider Own | 19.77% | Shs Outstand | 7.3M | Perf Week | -16.04% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 70.24% | Insider Trans | -5.7% | Shs Float | 5.8M | Perf Month | -19.99% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -2.24 | Inst Own | 22.69% | Short Float | 13.59% | Perf Quarter | -33.59% |
| Income | -0.16B | P/S | 3.48 | EPS this Y | -197.74% | Inst Trans | 20.66% | Short Ratio | 3.06 | Perf Half Y | -49.59% |
| Sales | 0.04B | P/B | 40.77 | EPS next 5Y | 7.19% | ROA | -459.6% | Short Interest | 0.79M | Perf YTD | 96.57% |
| Book/sh | 0.44 | P/C | 7.52 | EPS past 3/5Y | 42.63% 29.04% | ROE | -1603.48% | 52W High | -60.42% ($45.50) | Perf Year | -18.13% |
| Cash/sh | 2.39 | P/FCF | - | Sales past 3/5Y | 180.45% 54.16% | ROIC | -1729.46% | 52W Low | 262.3% ($4.97) | Perf 3Y | -75.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.33% | Gross Margin | 99.31% | Volatility(W/M) | 10.44% 12.34% | Perf 5Y | -95.69% |
| Dividend TTM | - | EV/Sales | 3.25 | Sales Y/Y TTM | 354.37% | Oper. Margin | -261.97% | ATR (14) | 2.58 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.25 | EPS Q/Q | -805.64% | Profit Margin | -435.83% | RSI (14) | 40.46 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.25 | Sales Q/Q | 166.66% | SMA20 | -8.54% ($19.69) | Beta | 2.81 | Target Price | $88 |
| Payout | - | Debt/Eq | 3.81 | Earnings | 2026/8/14 | SMA50 | -28.05% ($25.03) | Rel Volume | 0.55 | Prev Close | $19.84 |
| Employees | 29 | LT Debt/Eq | 3.11 | EPS/Sales Surpr. | -1328.4% 162.57% | SMA200 | -15.66% ($21.35) | Avg Volume(3M) | 0.26M | Price | $18.01 |
| IPO | 2018/1/2 | Option/Short | No/Yes | Trades | 1385 | Volume | 141,727 | Change | -9.22% |
🧬 Cue Biopharma is a clinical-stage biotech developing therapeutics for autoimmune diseases and oncology based on its proprietary platform for the precise modulation of immune cells. By selectively targeting specific T cells to elicit only the desired immune response, the company is building a next-generation immuno-oncology and autoimmune pipeline aimed at achieving fundamental treatment while reducing side effects.
Over the past 1 year, roughly in the middle
60% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
CUE has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -197.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $348. Peers typically go for $877.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.7%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #328 of 597 in the industry
Based on market cap of $131M.
FAQ
What kind of company is CUE?
CUE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CUE?
The market cap of CUE is approximately $131M, ranking 4,318 within its sector.
What is the 52-week high and low for CUE?
CUE has recorded a 52-week high of $45.50 and a low of $4.97.
